<DOC>
	<DOCNO>NCT00003556</DOCNO>
	<brief_summary>Phase I trial study effectiveness vaccine therapy treat patient melanoma treat surgery . Vaccines may make body build immune response may kill tumor cell . Combining one vaccine may kill tumor cell .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect associate ALVAC-hB7.1 alone combine ALVAC-hIL-12 patient surgically incurable melanoma . II . Characterize inflammatory lymphokine response regimen patient . III . Examine extent nodule regression , humoral immune response , cytolytic T cell activity regimen patient . OUTLINE : This dose escalation study ALVAC-hB7.1 Patients receive ALVAC-hB7.1 alone combine ALVAC-hIL-12 intratumorally day 1 , 4 , 8 , 11 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat dose level ALVAC-hB7.1 . The maximum tolerate dose define dose ALVAC-hB7.1 1 5 patient experience dose limit toxicity . Patients follow 1 , 2 , 4 , 8 , 11 , 15 , 22 , 43 day first vaccination .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma surgically incurable At least one dermal , subcutaneous lymph node metastasis evaluable local response accessible injection If one accessible lesion available , must least 2 cm If two accessible lesion exist , none require least 2 cm PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Leukocyte count least 3,000/mm3 Platelet count least 120,000/mm3 SGOT alkaline phosphatase less 5 time normal Bilirubin le 1.5 mg/dL ( unless secondary hepatic metastasis ) BUN le 40 mg/dL Creatinine le 2.5 mg/dL No evidence congestive heart failure , unstable angina , serious cardiac arrhythmia Not positive hepatitis B virus Not positive HIV No history allergy vaccinia virus No evidence primary tumor except basal cell carcinoma , squamous cell skin carcinoma , carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception No underlying immunodeficiency disorder PRIOR CONCURRENT THERAPY : At least 30 day since prior biologic therapy ( e.g. , interferon IL2 ) At least 30 day since prior chemotherapy No concurrent steroid At least 30 day since prior radiotherapy Prior radiotherapy great 50 % nodal group No prior splenectomy No concurrent drug affect immune function ( e.g. , glucocorticoid cimetidine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>